Acquisition - March 23, 2015
Deal for Genmab Holding, iDD
Genmab Holding B.V. a subsidiary of Genmab A/S, entered into an agreement to purchase antibodies and related patents from iDD Biotech SAS. The pre-clinical stage antibodies are directed to DR5, also known as Trail Receptor 2 (TRAIL-R2), an emerging cancer target. Under the terms of the agreement, Genmab is expected to pay iDD Biotech EUR 2.5 […]
Economic Analysis - December 15, 2014
Expired Patents to Lower Sales
Pharmaceutical companies will suffer an estimated $65 billion drop in sales by 2019 due to the patent expirations of several leading drugs, and AstraZeneca will be one of the hardest hit, according to research and consulting firm GlobalData. Besides AstraZeneca, the company’s report states that the drug makers hit hardest will include Otsuka and Eli […]
Regulatory compliance - December 9, 2014
AstraZeneca Scores Victory in Pay-for-Delay Case
In what could become a significant decision for the pharmaceutical industry, a jury in U.S. federal court found that AstraZeneca’s deal with Ranbaxy Laboratories to settle a patent fight over its heartburn medication Nexium did not violate antitrust laws. A group of pharmacies, wholesalers and insurers had sued over the agreement. As Bloomberg reported, this is the […]
